Camp4 Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Cash & Equivalents	64.04	38.38	83.19
Cash & Short-Term Investments	64.04	38.38	83.19
Cash Growth	66.86%	-53.86%	-
Other Receivables	0.11	0.44	0.68
Receivables	0.11	0.44	0.68
Prepaid Expenses	0.93	0.36	0.16
Other Current Assets	1.31	0.83	0.38
Total Current Assets	66.38	40.01	84.41
Property, Plant & Equipment	10.3	13.31	16.79
Other Long-Term Assets	1.62	1.62	1.35
Total Assets	78.31	54.95	102.55
Accounts Payable	1.21	1.04	2.15
Accrued Expenses	4.3	3.01	3.17
Current Portion of Long-Term Debt	0.09	0.41	-
Current Portion of Leases	3.09	3.06	2.37
Current Unearned Revenue	0.39	-	-
Other Current Liabilities	0.54	0.29	0.26
Total Current Liabilities	9.6	7.81	7.95
Long-Term Debt	-	0.09	-
Long-Term Leases	5.56	8.64	10.03
Other Long-Term Liabilities	0	0	-0.04
Total Liabilities	15.16	16.53	17.93
Common Stock	0	0	0
Additional Paid-In Capital	274.9	36.23	33.14
Retained Earnings	-211.75	-159.96	-110.67
Total Common Equity	63.14	-123.73	-77.53
Shareholders' Equity	63.14	38.42	84.62
Total Liabilities & Equity	78.31	54.95	102.55
Total Debt	8.73	12.18	12.4
Net Cash (Debt)	55.31	26.2	70.8
Net Cash Growth	111.12%	-63.00%	-
Net Cash Per Share	11.79	66.33	226.69
Filing Date Shares Outstanding	20.15	0.46	0.31
Total Common Shares Outstanding	20.15	0.46	0.31
Working Capital	56.79	32.21	76.46
Book Value Per Share	3.13	-268.57	-248.26
Tangible Book Value	63.14	-123.73	-77.53
Tangible Book Value Per Share	3.13	-268.57	-248.26
Machinery	5.57	4.78	4.17
Leasehold Improvements	4.52	4.52	4.52

Updated Nov 21, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q